From Our 2012 Archives
Gleevec Approval Widened to Include Rare Cancer
WEDNESDAY, Feb. 1 (HealthDay News) -- U.S. Food and Drug Administration approval for the Novartis drug Gleevec has been expanded to include adults who have had surgical removal of CD117-positive gastrointestinal stromal tumors (GIST), the agency said in a news release.
Latest Cancer News
GIST is a rare cancer that forms in cells that line the walls of the GI tract, including the stomach. Such cells play a role in food digestion and other bodily processes, the FDA said.
Gleevec's label will be updated to include clinical study results about CD117-positive GIST. The drug significantly increased patient survival when taken for 36 months, compared to the standard 12 months, the FDA said.
Novartis is based in East Hanover, N.J.
-- Scott Roberts
Copyright © 2012 HealthDay. All rights reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions